TargED Biopharmaceuticals B.V., a clinical-stage biotech company developing targeted treatments for thrombotic diseases, has closed a €21.5 million Series A extension led by BioGeneration Ventures (BGV). Existing investors, including Andera Partners, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures, and Curie Capital, also participated, bringing the company’s total Series A funding to more than €60 million.
The company said the new capital will accelerate clinical development of its lead program, TGD001, a first-in-class targeted thrombolytic designed to treat a broad range of thrombotic events by degrading both von Willebrand factor (VWF) and fibrin. TargED plans to advance TGD001 into two Phase 1/2 clinical studies, expand trial sites across Europe and the U.S., and expects first data in 2026.
In December 2025, TargED reported positive Phase 1 first-in-human results for TGD001, citing a favorable safety profile with no spontaneous bleeding events and potent thrombolytic activity. The company presented the data in an oral session at the American Society of Hematology (ASH) Annual Meeting.
TGD001 is an antibody-enzyme fusion protein that binds to VWF and promotes site-specific clot breakdown through the enzyme urokinase. TargED says that, unlike currently approved therapies, TGD001 leverages the ubiquitous presence of VWF in all clots to enable broad clot lysis by degrading both VWF and fibrin. The program has been evaluated in a Phase 1 trial and is planned for development in acute ischemic stroke and thrombotic microangiopathies, including immune thrombotic thrombocytopenic purpura.
Founded in 2020 as a spin-out from University Medical Center Utrecht, TargED has also received a blended finance grant from the European Innovation Council (EIC) Accelerator Program in 2025, according to the company.
KEY QUOTES
“This investment marks an important inflection point for TargED. We are thrilled to welcome BioGeneration Ventures to our strong syndicate and grateful for the continued confidence of all our existing investors.”
“The momentum behind TGD001 continues to build — from compelling preclinical data to encouraging first clinical use — and this financing enables us to move decisively into the next stage of development.”
“We believe TGD001 has the potential to fundamentally reshape the treatment of thrombosis, offering a novel approach to universally dissolving clots across multiple life-threatening indications.”
Kristof Vercruysse, Chief Executive Officer, TargED Biopharmaceuticals
“We are delighted to partner with TargED as it has been remarkable to watch their evolution into a leading clinical-stage company in targeted thrombolysis.”
“The team has consistently executed with focus, scientific rigor, and speed, transforming a bold academic concept into a highly differentiated clinical asset.”
“Leading this Series A extension reflects our deep conviction in both TGD001’s potential to redefine how thrombotic diseases are treated and in TargED’s ability to deliver on that promise.”
Rianne Ellenbroek, Principal, BioGeneration Ventures
